Why are steroids not routinely recommended for patients with glioma?

Why Steroids Are Not Routinely Recommended for Glioma Patients

Steroids should only be used in glioma patients who have symptomatic neurological deficits from tumor-associated edema, not routinely or prophylactically, because strong evidence links steroid use to inferior survival in glioblastoma and they interfere with both standard treatments and immunotherapy approaches. 1

The Core Problem: Survival Impact

The most critical issue is that steroid use is independently associated with worse survival outcomes in glioblastoma patients. Strong evidence demonstrates that:

• Steroid use at 6 months after diagnosis independently predicts inferior survival, even after correcting for known prognostic factors 2
• Corticosteroid use during radiotherapy is an independent indicator of shorter survival across multiple patient cohorts 3
• Early withdrawal of steroids (within 7 days postoperatively) is associated with improved survival at 6 months (HR 0.57), 1 year (HR 0.65), and 2 years (HR 0.70) 4

Mechanisms of Harm

Steroids compromise outcomes through multiple pathways:

Treatment Interference:

• Dexamethasone decreases tumor cell proliferation, which paradoxically protects cancer cells from radiotherapy and chemotherapy-induced genotoxic stress (these treatments target dividing cells) 3
• Steroids suppress antitumor immune responses, which is particularly detrimental given current interest in immunotherapy approaches 1
• They may induce chemoresistance and modulate DNA damage repair pathways within the tumor microenvironment 5

Direct Toxicities:

• Increased risk of Pneumocystis jiroveci pneumonia (PJP)
• Diabetes and arterial hypertension
• Osteoporosis and myopathy
• Psychiatric adverse effects
• Meningitis, CSF leak, intracranial hemorrhage, and venous thromboembolism 1, 4
• Impaired neurocognitive functioning, particularly memory and executive function 6

When Steroids ARE Indicated

Use steroids ONLY when patients have symptomatic neurological deficits requiring relief 1. The specific algorithm:

1. Asymptomatic patients with no mass effect: Do NOT use steroids 1

2. Mild symptoms from mass effect:

   • Start dexamethasone 4-8 mg/day (single daily dose, oral or IV)
   • Use the minimum effective dose 1

3. Moderate to severe symptoms with increased intracranial pressure:

   • Consider higher doses (16 mg/day or more) 7
   • Still aim for lowest effective dose

4. Perioperative use:

   • Prophylactic steroids perioperatively are increasingly discouraged 1
   • If used, withdraw within 7 days postoperatively 4

5. During radiotherapy:

   • Do NOT use prophylactically in asymptomatic patients 8
   • Only for symptomatic relief when absolutely necessary

Critical Management Principles

Tapering Strategy:

• Taper to the lowest dose needed to control symptoms as rapidly as clinically tolerated 1
• Typical taper over 2-4 weeks, but longer periods may be needed for long-term users 1
• Clinically-asymptomatic patients seldom require anti-oedema treatment 1

PJP Prophylaxis:

• Required for steroid treatment >4 weeks, during RT or chemotherapy, or with lymphocyte count <1000/ml
• Use trimethoprim-sulfamethoxazole 1

Drug of Choice:

• Dexamethasone is preferred due to potent glucocorticoid activity, minimal mineralocorticoid effects, and long half-life allowing single daily dosing 1

Common Pitfalls to Avoid

1. Prophylactic use: Never use steroids prophylactically in asymptomatic patients, perioperatively, or during radiotherapy 1, 8

2. Prolonged use: Steroid use at 3 months predicts use at 6 months (OR 7.66), creating a cascade of continued exposure 2

3. High doses: Higher doses (8-16 mg) show no superior benefit over 4 mg but significantly increase side effects 1

4. Interaction with immunotherapy: Critical evaluation is mandatory when considering immunotherapeutics, as steroids may be detrimental 1

5. Drug interactions: Steroids interact with antiepileptic drugs and other concurrent medications 1

The evidence is clear: minimize steroid dose and duration whenever clinically feasible 2. The biological mechanisms mediating survival detriment are increasingly understood, and the data support cautious, symptom-driven use only.